SINGAPORE, SINGAPORE--(Marketwire - July 06, 2010) - Zecotek Photonics Inc. (TSX VENTURE: ZMS)(FRANKFURT: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institute of Health (NIH) has released positive test results conducted on Zecotek's proprietary Tunable Green Fiber Laser. Dr. William Telford, the Director of the National Cancer Institute Flow Cytometry Core Laboratory in Bethesda MD, reported that Zecotek's Tunable Green Fiber Laser provides both lower noise and enhanced detection resolution over the entire tunable range of 540nm to 550nm, resulting in an improvement in data collection and an increase in analytical capability.
"The test results from the National Cancer Institute show that Zecotek's Tunable Green Fiber Laser performs better than alternative lasers in an area of research that directly contributes to the advancement of bio-instrumentation," said Dr. A.F. Zerrouk, Chairman, President and CEO of Zecotek. "Dr. Telford is a highly respected scientist and his research is closely followed by industry as well as other leading researchers. His observations on the advantages of our Tunable Green Fiber Lasers for flow cytometry fully support the commitment and efforts we have made to bring this important technology to market."
Dr. Telford presented the test results at the prestigious Congress for the International Advancement of Cytometry (CYTO), held in Seattle in early May and attended by leading researchers, practitioners and bio-instrumentation manufacturers. He noted that both Zecotek's tunable and fixed wavelength Green Fiber Lasers are ideal for utilizing the many new fluorescent probes for various applications, including fundamental research in immunology, hematology, organ transplantation and other biomedical fields. Dr. Telford also noted that tunable lasers will now make virtually any fluorochrome accessible to analysis and importantly will also provide for new types of flourochromes not presently available to research. According to Dr. Telford, tuneability "will become a future requirement by end users and the research community."
Zecotek Photonics Inc. (TSX VENTURE: ZMS)(FRANKFURT: W1I) is a photonics technology company developing leading-edge products: crystals, photo detectors, lasers, imaging and 3D display technologies, for medical, biotech, industrial, nanotech and atomic/molecular science applications. Founded in 2003, the company has three distinct operating divisions: Laser Systems, Imaging Systems and 3D Display Systems and labs located in Canada, the United States, Singapore, Malaysia and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.